20 May 2025
Cardiogenic shock and high-risk interventions with percutaneous mechanical circulatory support: new evidence and insights
Sponsored by Johnson & Johnson MedTech – Heart Recovery
Anchorperson:
A. Chieffo
Summary
This EuroPCR 2025 session offers a comprehensive update on cardiogenic shock and high-risk PCI, featuring expert analysis of the DanGer-SHOCK and ECLS-SHOCK trials, new insights one year after DanGer-SHOCK, and practical considerations for managing PCI in patients with severely reduced LVEF. Expect to gain a deeper understanding of mechanical support strategies, survival optimisation, and the latest consensus on treating patients unsuitable for surgery.
Learning Objectives
- To learn the latest data on Impella in cardiogenic shock
- To learn on how to improve survival of cardiogenic shock patients
- To see latest data and EAPCI consensus on high-risk PCI in patients unsuitable for surgery
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)
/slide008.jpg)
/slide009.jpg)
/slide010.jpg)
/slide011.jpg)
/slide012.jpg)
/slide013.jpg)
/slide014.jpg)
/slide015.jpg)
/slide016.jpg)
/slide017.jpg)
/slide018.jpg)
/slide019.jpg)
/slide020.jpg)
/slide021.jpg)
/slide022.jpg)
/slide023.jpg)
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)
/slide008.jpg)
/slide009.jpg)
/slide010.jpg)
/slide011.jpg)
/slide012.jpg)
/slide013.jpg)
/slide014.jpg)
/slide015.jpg)
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)
/slide008.jpg)
/slide009.jpg)
/slide010.jpg)
/slide011.jpg)
/slide012.jpg)
/slide013.jpg)
/slide014.jpg)
/slide015.jpg)
/slide016.jpg)
/slide017.jpg)
/slide018.jpg)
/slide019.jpg)
/slide020.jpg)
/slide021.jpg)
/slide022.jpg)
/slide023.jpg)
/slide024.jpg)
/slide025.jpg)
/slide026.jpg)